Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Becton Dickinson detracted from relative performance in the second quarter following a worse-than-expected fiscal quarter earnings report in which the company felt the impact of cuts to the National Institutes of Health (NIH) budget and uncertainty around future cuts. Furthermore, forward earnings...
— Mr. Fitzpatrick
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Becton, Dickinson and Company
Our positions in Becton, Dickinson and Company common stock (NYSE: BDX) made notable positive contributions.
Becton Dickinson offers an attractive recurring revenue stream and leadership across diverse medical categories. Having waited out...
More institutional theses from Aristotle Core Equity Fund
Chart Industries posted positive performance as preliminary 2025 outlooks indicated robust 39% earnings growth despite a Q3 quarterly miss. Management reiterated solid...
The fund established a long position in CrowdStrike to capture secular growth in enterprise cloud migration and security spending. The company's unified...
Aristotle initiated a position in GE Aerospace, citing its dominant position in high-barrier commercial engine manufacturing and long OEM order backlogs. Following significant corporate...